MiNK Therapeutics, Inc. (INKT) Stock Analysis — Probabli.AI
AI-powered analysis for INKT (MiNK Therapeutics, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $11.27 · Market cap: $59.1M · AI outlook: Bullish
MiNK Therapeutics (INKT), currently trading at $11.27, has a strong bullish outlook driven by high analyst targets, a solid clinical pipeline, and strategic partnerships with global pharmaceutical companies. Its historical success in clinical trials and consistent earnings surprises make it an exciting growth prospect within the biopharma sector, albeit with significant competitive and financial…
Probabilistic 1-Year Outlook
- Bull 60% · Neutral 30% · Bear 10%
- 1-year price estimates — P10: $7 / P50: $18 / P90: $30
- The combination of analyst consensus (Strong Buy with a mean target approximately 3x current price), ongoing licensing deals, partnerships, and upcoming FDA submission provides strong bullish momentum for MiNK…
5-Year Outlook
- Bull 50% · Neutral 40% · Bear 10%
- 5-year price estimates — P10: $18 / P50: $60 / P90: $100
SWOT Highlights
- Strength: Rapid growth potential due to innovative pipeline and development.
- Strength: Strong strategic partnerships enhancing credibility and resources.
- Risk: High competition from rival therapies in the biopharmaceutical space.
- Risk: Current financial losses put pressure on operational sustainability.
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
2 Wall Street analysts rate INKT a STRONG BUY with a mean price target of $35.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
INKT forecast details · INKT sentiment details
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.